Skip to content

Bayer Thrombosis Drug Asundexian Shows Positive Study Result

Herbicide Research Work at Bayer AG CropSciences Facility
Photographer: Alex Kraus/Bloomberg
Updated on

Bayer AG said a new thrombosis prevention drug showed positive results in a clinical study designed to determine its safety and optimal dosing.

The company’s investigational treatment asundexian demonstrated a 67% reduction in ISTH major and clinically relevant non-major bleeding in patients with atrial fibrillation at risk of stroke, Bayer said Sunday. Asundexian is a so-called factor 11a inhibitor and was being compared to a drug sold under the brand name Eliquis by Pfizer Inc. and Bristol-Myers Squibb Co.